Editor’s highlights from Future Oncology – October 2020

In this latest instalment of his regular monthly column, Louis Gautier, Commissioning Editor of Future Oncology, exclusively shares some of his top picks from the recent journal issues, which we have made freely available for you, Oncology Central members! Check out Louis’ highlights below: FIGHT-302: first-line pemigatinib vs gemcitabine + cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements Advances in genomic profiling techniques are continuing to identify genetic alterations that drive carcinogenesis across multiple tumor types, one of which is the FGFR gene. The incidence of FGFR mutations in cholangiocarcinomas has been reported as around 11% [1] and a number of ongoing...